Drug resistance in colon cancer Journal Article


Authors: Gorlick, R.; Bertino, J. R.
Article Title: Drug resistance in colon cancer
Abstract: A significant obstacle for the successful management of patients with colorectal cancer is intrinsic drug resistance or, in patients who respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms, including alterations in drug influx, drug efflux, intracellular metabolic activation, and intracellular catabolism, or through alterations in the drug's target. In addition, alterations in genes involved in the regulation of the cell cycle or in DNA damage repair may result in a cell becoming resistant to chemotherapy. In this chapter, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines and raltitrexed (Tomudex; Zeneca Pharmaceuticals, Wilmington, DE) are reviewed, focusing on newer studies using gastric and colorectal tumor samples obtained from patients. Clinical trials using this new information are anticipated.
Keywords: cancer chemotherapy; fluorouracil; animals; cell cycle; gene expression; antimetabolites, antineoplastic; drug resistance, neoplasm; cancer resistance; colorectal neoplasms; enzyme inhibitors; colorectal tumor; colon cancer; drug metabolism; thymidylate synthase; folic acid antagonists; quinazolines; fluoropyrimidine; stomach tumor; thiophenes; raltitrexed; humans; human; priority journal; article
Journal Title: Seminars in Oncology
Volume: 26
Issue: 6
ISSN: 0093-7754
Publisher: Elsevier Inc.  
Date Published: 1999-12-01
Start Page: 606
End Page: 611
Language: English
PUBMED: 10606253
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 16 August 2016 -- Source: Scopus
Citation Impact
MSK Authors
  1. Richard G Gorlick
    121 Gorlick
  2. Joseph Bertino
    363 Bertino